What is Progentec Diagnostics?
Progentec Diagnostics is dedicated to enhancing patient outcomes and accessibility for individuals suffering from autoimmune diseases. The company leverages a combination of clinically validated diagnostic interventions and advanced digital technologies to achieve its mission. Through strategic partnerships with global research institutions and healthcare providers, Progentec aims to mitigate mortality and morbidity rates associated with chronic health conditions, while simultaneously improving care management and service delivery.
How much funding has Progentec Diagnostics raised?
Progentec Diagnostics has raised a total of $5.2M across 2 funding rounds:
Series A
$5M
Debt
$172K
Series A (2020): $5M with participation from NMC Health, Oklahoma Angel Capital Fund II, Stanford University, Burns & Stowers Investments LLC, OCA Ventures, Plains Venture Partners, Oklahoma Seed Capital Fund, Oklahoma Medical Research Foundation, and Mayo Clinic
Debt (2021): $172K led by PPP
Key Investors in Progentec Diagnostics
Stanford University
Founded in 1891, Stanford University is a world-leading research institution known for its entrepreneurial spirit and interdisciplinary approach to problem-solving, contributing significantly to advancements across various scientific and humanities fields.
OCA Ventures
OCA Ventures is dedicated to assisting entrepreneurs in the development of successful companies, providing support and resources to help startups thrive and fostering innovation and growth among emerging businesses.
Mayo Clinic
Mayo Clinic is a global healthcare organization specializing in integrated clinical practice, education, and medical research, recognized for its multidisciplinary approach to patient care and commitment to medical advancement.
What's next for Progentec Diagnostics?
With the recent major strategic investment, Progentec Diagnostics is poised for significant expansion and further development of its innovative diagnostic platforms. This capital infusion is expected to accelerate the company's growth trajectory, enabling enhanced research and development efforts, broader market penetration, and the scaling of its digital health solutions. The company's focus on autoimmune diseases, coupled with its commitment to integrating cutting-edge technology, positions it for continued leadership in the diagnostic sector.
See full Progentec Diagnostics company page
